首页> 外文OA文献 >Protocol for a randomised control trial of methylnaltrexone for the treatment of opioid-induced constipation and gastrointestinal stasis in intensive care patients (MOTION)
【2h】

Protocol for a randomised control trial of methylnaltrexone for the treatment of opioid-induced constipation and gastrointestinal stasis in intensive care patients (MOTION)

机译:甲基纳曲酮用于治疗重症监护患者阿片类药物引起的便秘和胃肠淤滞的随机对照试验方案(mOTION)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Gastrointestinal dysmotility and constipation are common problems in intensive care patients. The majority of critical care patients are sedated with opioids to facilitate tolerance of endotracheal tubes and mechanical ventilation, which inhibit gastrointestinal motility and lead to adverse outcomes. Methylnaltrexone is a peripheral opioid antagonist that does not cross the blood-brain barrier and can reverse the peripheral side effects of opioids without affecting the desired central properties. This trial will investigate whether methylnaltrexone can reverse opioid-induced constipation and gastrointestinal dysmotility.This is a single-centre, multisite, double-blind, randomised, placebo-controlled trial. 84 patients will be recruited from 4 intensive care units (ICUs) within Imperial College Healthcare NHS Trust. Patients will receive intravenous methylnaltrexone or placebo on a daily basis if they are receiving opioid infusion to facilitate mechanical ventilation and have not opened their bowels for 48 hours. All patients will receive standard laxatives as per the clinical ICU bowel protocol prior to randomisation. The primary outcome of the trial will be time to significant rescue-free laxation following randomisation. Secondary outcomes will include tolerance of enteral feed, gastric residual volumes, incidence of pneumonia, blood stream and Clostridium difficile infection, and any reversal of central opioid effects.The trial protocol, the patient/legal representative information sheets and consent forms have been reviewed and approved by the Harrow Research Ethics Committee (REC Reference 14/LO/2004). An independent Trial Steering Committee and Data Monitoring Committee are in place, with patient representation. On completion, the trial results will be published in peer-reviewed journals and presented at national and international scientific meetings.2014-004687-37; Pre-results.
机译:胃肠动力障碍和便秘是重症监护患者的常见问题。大多数重症监护患者均使用阿片类药物镇静,以促进气管插管和机械通气的耐受性,这会抑制胃肠蠕动并导致不良后果。甲基纳曲酮是一种外周阿片类药物拮抗剂,它不会穿过血脑屏障,并且可以逆转阿片类药物的外周副作用而不会影响所需的中心特性。该试验将研究甲基纳曲酮是否可以逆转阿片类药物引起的便秘和胃肠道动力障碍,这是一项单中心,多部位,双盲,随机,安慰剂对照试验。帝国大学医疗保健NHS信托基金内的4个重症监护病房(ICU)将招募84名患者。如果患者正在接受阿片类药物输注以促进机械通气并且在48小时内未打开肠,则每天将接受静脉注射甲基纳曲酮或安慰剂。在随机分组之前,所有患者将根据临床ICU肠方案接受标准泻药。该试验的主要结果是在随机分组后有时间进行大量的免营救。次要结果将包括肠内饲料耐受性,胃残余量,肺炎的发生率,血流和艰难梭菌感染以及中枢阿片类药物作用的任何逆转。试验方案,患者/法律代表资料单和同意书均已审查并由Harrow研究伦理委员会批准(REC参考14 / LO / 2004)。设有独立的审判指导委员会和数据监测委员会,并有患者代表。完成后,试验结果将在同行评审的期刊上发表,并在国家和国际科学会议上发表。2014-004687-37;结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号